PLEDPHARMA AB (PUBL) Inactive Instrument
PledPharma AB (publ) Share Price Nasdaq Stockholm
Equities
SE0003815604
Biotechnology & Medical Research
| Sales 2024 * | 58.49M 5.41M 431M | Sales 2025 * | 496M 45.82M 3.65B | Capitalization | 1.89B 175M 13.95B |
|---|---|---|---|---|---|
| Net income 2024 * | -291M -26.91M -2.14B | Net income 2025 * | 171M 15.81M 1.26B | EV / Sales 2024 * | 34.1 x |
| Net Debt 2024 * | 103M 9.49M 756M | Net cash position 2025 * | 61.97M 5.73M 457M | EV / Sales 2025 * | 3.7 x |
| P/E ratio 2024 * |
-6.81
x | P/E ratio 2025 * |
9.46
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 72.61% |
More Fundamentals
* Assessed data
More news
Latest transcript on PledPharma AB (publ)
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 48 | 15/06/17 | |
Yilmaz Mahshid
DFI | Director of Finance/CFO | 45 | 30/12/17 |
| Chief Tech/Sci/R&D Officer | - | 04/05/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mats Blom
BRD | Director/Board Member | 59 | 31/03/21 |
| Director/Board Member | 50 | 31/12/19 | |
Thomas Lönngren
CHM | Chairman | 73 | 31/03/21 |
Egetis Therapeutics AB (publ), formerly PledPharma AB (publ) is a Sweden-based pharmaceutical drug development company, focusing on projects in late-stage development for treatment of diseases with unmet medical needs in the orphan drug segment. The Companyâs pipeline include Emcitate developed for the treatment of MCT8 deficiency, PledOx developed to reduce nerve damage associated with chemotherapy and Aladote developed to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning.
Calendar
05/05/2024
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| -1.43% | 103B | |
| +8.96% | 101B | |
| +4.40% | 23.07B | |
| -12.15% | 22.23B | |
| -4.36% | 18.05B | |
| -39.98% | 17.18B | |
| -10.04% | 16.94B | |
| +6.79% | 14.07B | |
| +38.61% | 12.35B |
